Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Mol Cancer Ther ; 1(10): 869-76, 2002 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-12492120

RESUMEN

The inverse association between a high enterolactone (ENL) concentration in both urine and serum, and the risk of breast cancer found in epidemiological studies suggests a chemopreventive action for ENL. However, no causal relationship has been established in clinical studies or in experimental models for breast cancer. In the present study, the potential chemopreventive action of p.o. administered ENL (1 or 10 mg/kg of body weight) was tested in 7,12-dimethylbenz(a)anthracene-induced mammary cancers of the rat. Rats were maintained on a standard open-formula chow diet. Daily p.o. administration of ENL at a dose of 10 mg/kg of body weight for 7 weeks significantly inhibited tumor growth. The growth-inhibitory effect of ENL was more pronounced on the new tumors, which developed during the treatment period, but ENL also inhibited the growth of those tumors established before the start of the lignan administration. The rat serum concentration of ENL, which illustrated a permanent positive effect on breast cancer growth, was 0.4 microM, which is >10-fold as compared with the serum concentrations found in the general human population. The effect of ENL was not restricted to any specific histological tumor type. ENL was demonstrated to act as a weak aromatase inhibitor in vitro and to reduce the relative uterine weight of the 7,12-dimethylbenz(a)anthracene-treated nonovariectomized rats. However, in a short-term assay ENL had no effect on the uterine growth of the intact or androstenedione-treated immature rats. Thus, the mechanism of the ENL action and its minimum or optimal daily dose remains to be clarified.


Asunto(s)
4-Butirolactona/análogos & derivados , 4-Butirolactona/farmacocinética , 9,10-Dimetil-1,2-benzantraceno , Isoflavonas , Lignanos/farmacocinética , Neoplasias Mamarias Animales/tratamiento farmacológico , 4-Butirolactona/sangre , 4-Butirolactona/orina , 9,10-Dimetil-1,2-benzantraceno/farmacología , Animales , Inhibidores de la Aromatasa , Carcinógenos , División Celular/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Estrógenos/farmacología , Estrógenos no Esteroides/sangre , Estrógenos no Esteroides/orina , Femenino , Lignanos/sangre , Lignanos/metabolismo , Lignanos/orina , Modelos Químicos , Tamaño de los Órganos , Fitoestrógenos , Preparaciones de Plantas , Ratas , Ratas Sprague-Dawley , Factores de Tiempo , Útero/efectos de los fármacos
2.
J Chromatogr B Analyt Technol Biomed Life Sci ; 777(1-2): 311-9, 2002 Sep 25.
Artículo en Inglés | MEDLINE | ID: mdl-12270222

RESUMEN

The quantity of mammalian lignans enterolactone (ENL) and enterodiol (END) and of plant lignans secoisolariciresinol (SECO) and 7-hydroxymatairesinol (HMR) excreted in a 24-h rat urine sample was measured after a single p.o. dose of an equivalent quantity of secoisolariciresinol diglycoside (SDG), secoisolariciresinol (SECO), matairesinol (MR), 7-hydroxymatairesinol (HMR) and ENL. Plant lignans (SECO and HMR) were partially absorbed as such. The aglycone form of SECO was more efficiently converted into mammalian lignans END and ENL than the glycosylated form, SDG. Of plant lignans, MR produced the highest quantities of ENL: the quantity was over twofold compared with HMR or SDG. The majority of the animals, which had been given SECO, excreted higher quantities of END than ENL into urine, but ENL was the main lignan metabolite after SDG. The highest quantities of ENL in urine were measured after the administration of ENL as such. The (-)SECO isolated from Araucaria angustifolia was converted into (-)ENL only. The administration of (-)SDG, which was shown to produce (+)SECO, resulted in excretion of (+)ENL only and (-)HMR was converted into (-)ENL only. This confirmed that the absolute configurations at C8 and C8' are not changed during the microbial metabolism. Whether the biological effects are enantiomer-specific, remains to be resolved.


Asunto(s)
4-Butirolactona/análogos & derivados , 4-Butirolactona/biosíntesis , Lignanos/biosíntesis , Lignanos/farmacología , 4-Butirolactona/química , 4-Butirolactona/orina , Animales , Cromatografía Líquida de Alta Presión , Lignanos/química , Lignanos/orina , Masculino , Espectrometría de Masas , Ratas , Ratas Sprague-Dawley , Estereoisomerismo , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA